SCHEMBL1668637

SCHEMBL1668637

CC1(C)C2CCC1(C)C(O)C2O

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.36
DPP4 P27487 1/20 0.35
SHBG P04278 2/20 0.32
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP3A4 P08684 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29761172 1.00 CNR2 (0.36) CNR2DPP4SHBGMEN1ALDH1A1
SCHEMBL5407267 1.00 CNR2 (0.36) CNR2DPP4SHBGMEN1ALDH1A1
SCHEMBL1668635 1.00 CNR2 (0.36) CNR2DPP4SHBGMEN1ALDH1A1
SCHEMBL30148076 1.00 CNR2 (0.36) CNR2DPP4SHBGMEN1ALDH1A1
SCHEMBL13320075 0.79 CNR2 (0.35) CNR2DPP4SHBG
SCHEMBL24052391 0.77 CNR2 (0.35) CNR2DPP4SHBGMEN1ALDH1A1
SCHEMBL9360142 0.77 CNR2 (0.35) CNR2DPP4SHBG
SCHEMBL253323 0.77 CNR2 (0.35) CNR2DPP4SHBG
SCHEMBL7673902 0.77 CNR2 (0.35) CNR2DPP4SHBG
SCHEMBL6507028 0.77 CNR2 (0.35) CNR2DPP4SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2485678-A1 COFERONS AND METHODS OF MAKING AND USING THEM Cornell University (US) 2012-08-15 EP claimed
WO-2011043817-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2011-04-14 WO claimed
US-7250157-B2 Dermatological compositions and methods APPLIED GENETICS INCORPORATED DERMATICS (US) 2007-07-31 US claimed
US-20060120976-A1 Dermatological compositions and methods APPLIED GENETICS INCORPORATED DERMATICS (US) 2006-06-08 US claimed
US-6955804-B2 Dermatological compositions and methods APPLIED GENETICS INCORPORATED DEMATICS (US) 2005-10-18 US claimed
US-20040067209-A1 Dermatological compositions and methods APPLIED GENETICS INCORPORATED DERMATICS 2004-04-08 US claimed
US-6623724-B2 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues APPLIED GENETICS INCORPORATED DERMATICS 2003-09-23 US claimed
US-20020141952-A1 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues APPLIED GENETICS INCORPORATED DERMATICS 2002-10-03 US claimed
WO-2002051395-A1 TREATMENT OF NEURODEGENERATIVE DISEASES CODON PHARMACEUTICALS, INC. (US) 2002-07-04 WO claimed
WO-1998055085-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS CODON PHARMACEUTICALS, INC. (US) 1998-12-10 WO claimed
EP-0391619-B1 Dental cements DEN MAT CORP (US) 1993-12-15 EP claimed
EP-0391619-A2 Dental cements DEN-MAT CORPORATION (US) 1990-10-10 EP claimed
JP-61138282-A None JP disclosed
EP-4705279-A1 RADICALLY POLYMERISABLE COMPOUND AND COMPOSITION Mühlbauer Technology GmbH (DE) 2026-03-11 EP disclosed
CN-119318614-A Cosmetic composition and application thereof 华熙生物科技股份有限公司 2025-01-17 CN disclosed
WO-2024227533-A1 RADICALLY POLYMERISABLE COMPOUND AND COMPOSITION MÜHLBAUER TECHNOLOGY GMBH (DE) 2024-11-07 WO disclosed
US-20020141952-A1 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues APPLIED GENETICS INCORPORATED DERMATICS 2002-10-03 US disclosed
WO-2002051395-A1 TREATMENT OF NEURODEGENERATIVE DISEASES CODON PHARMACEUTICALS, INC. (US) 2002-07-04 WO disclosed
WO-1998055085-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS CODON PHARMACEUTICALS, INC. (US) 1998-12-10 WO disclosed
JP-S61138282-A PREPARATION OF HOLOGRAM FUJITSU LTD 1986-06-25 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020141952-A1 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues TYR, MITF, MC1R CNR2 3791/4885DPP4 4520/4885SHBG 1150/4885
US-20060120976-A1 Dermatological compositions and methods TYR, MITF, ALPG CNR2 4006/4885DPP4 4119/4885SHBG 411/4885
US-20040067209-A1 Dermatological compositions and methods TYR, MITF, ALPG CNR2 4006/4885DPP4 4119/4885SHBG 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.